http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Province, M A (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
서진우, 오명균, 성태경 상지대학교 한의학연구소 2019 尙志韓醫論文集 Vol.7 No.1
Objectives: This study was carried out analyze the current state of Dementia Service in Gangwon Province and to investigate the role of Korean Medicine specialist for Dementia Service in Gangwon Province. Methods: We referred the data of current state of Dementia in Gangwon Province from Central Dementia Center and Dementia Center of Gangwon Province. The data of Korean medicine Service of Dementia or mild cognitive impairment(MCI) was investigated from the services taken in several public health centers or local governments. Results: In Gangwon Province, the medical institutions and clinics are less than other region. The Korean Medicine specialist and clinics are excluded in Dementia Service in Gangwon Province. Many Korean Medicine Dementia or MCI Services were productive and significantly effective in improvement of cognitive function and depressive emotion. Conclusion: More educational program to Korean Medicine specialist and more connections between Korean Medicine clinics and Health centers are needed
-
<i>CYP2D6</i> Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
Province, M A,Goetz, M P,Brauch, H,Flockhart, D A,Hebert, J M,Whaley, R,Suman, V J,Schroth, W,Winter, S,Zembutsu, H,Mushiroda, T,Newman, W G,Lee, M-T M,Ambrosone, C B,Beckmann, M W,Choi, J-Y,Dieudonn& C. V. Mosby 2014 Clinical Pharmacology & Therapeutics Vol. No.
<P>The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (<I>CYP2D6</I>) status and clinical outcomes in tamoxifen therapy. We performed a meta-analysis on data from 4,973 tamoxifen-treated patients (12 globally distributed sites). Using strict eligibility requirements (postmenopausal women with estrogen receptor–positive breast cancer, receiving 20 mg/day tamoxifen for 5 years, criterion 1); CYP2D6 poor metabolizer status was associated with poorer invasive disease–free survival (IDFS: hazard ratio = 1.25; 95% confidence interval = 1.06, 1.47; <I>P</I> = 0.009). However, <I>CYP2D6</I> status was not statistically significant when tamoxifen duration, menopausal status, and annual follow-up were not specified (criterion 2, <I>n</I> = 2,443; <I>P</I> = 0.25) or when no exclusions were applied (criterion 3, <I>n</I> = 4,935; <I>P</I> = 0.38). Although <I>CYP2D6</I> is a strong predictor of IDFS using strict inclusion criteria, because the results are not robust to inclusion criteria (these were not defined <I>a priori</I>), prospective studies are necessary to fully establish the value of <I>CYP2D6</I> genotyping in tamoxifen therapy.</P>
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
